Pravastatin Sodium 80 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 60
- Registration Number
- NCT00830258
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 30
- Registration Number
- NCT00829790
- Locations
- 🇺🇸
CEDRA Clinical Research, San Antonio, Texas, United States
Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00829673
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
Zaleplon 10 mg Capsules Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 42
- Registration Number
- NCT00829868
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 40
- Registration Number
- NCT00829530
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Zaleplon 10mg Capsules Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 40
- Registration Number
- NCT00829998
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 46
- Registration Number
- NCT00830219
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00829426
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 36
- Registration Number
- NCT00830024
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 16
- Registration Number
- NCT00829309
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
© Copyright 2024. All Rights Reserved by MedPath